Prilenia Therapeutics scores $62.5m Series
Prilenia Therapeutics B.V., a developer of novel treatments for neurodegenerative and neurodevelopmental disorders, has raised $62.5 million in Series A financing.
Prilenia Therapeutics B.V., a developer of novel treatments for neurodegenerative and neurodevelopmental disorders, has raised $62.5 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination